Floatz logo

Gm-Csf

Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow UniversityPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

180 Active assets in the Advanced Refractory Solid Tumors cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

Gm-Csf is also rated in:

melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
acute lymphoblastic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →